Afatinib free base

• CAT Number: I001295
• CAS Number: 439081-18-2 (free base)
• Molecular Formula: C24H25ClFN5O3
• Molecular Weight: 485.94
• Purity: ≥95%
• Synonyms: BIBW-2992; BIBW 2992; BIBW2992. Afatinib free base; trade name: Gilotrif, Tomtovok and Tovok.
• Target: RTK inhibitor
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4°Cfor short term (days to weeks), or -20 °C for long term (months).
• InChI: InChI=1S/C24H25ClFN5O3/c1-31(2)8-3-4-23(32)30-21-11-17-20(12-22(21)34-16-7-9-33-13-16)27-14-28-24(17)29-15-5-6-19(26)18(25)10-15/h3-6,10-12,14,16H,7-9,13H2,1-2H3,(H,30,32)(H,27,28,29)/b4-3+/t16-/m0/s1
• InChIKey: ULXXDDBFHOBEHA-CWDCEQMOSA-N
• SMILES: O=C(NC1=CC2=C(NC3=CC=C(F)C(Cl)=C3)N=CN=C2C=C1O[C@@H]4COCC4)/C=C/CN(C)C

Afatinib, also know as BIBW 2992, is an orally bioavailable dual receptor tyrosine kinase (RTK) inhibitor with potential antineoplastic activity. EGFR/HER2 tyrosine kinase inhibitor BIBW 2992 irreversibly binds to and inhibits human epidermal growth factor receptors 1 and 2 (EGFR-1; HER2), which may result in the inhibition of tumor growth and angiogenesis. EGFR/HER2 are RTKs that belong to the EGFR superfamily; both play major roles in tumor cell proliferation and tumor vascularization and are overexpressed in many cancer cell types. Afatinib is approved in much of the world (including the United States, Canada, the United Kingdom and Australia) for the treatment of metastatic non-small cell lung carcinoma (NSCLC), developed by Boehringer Ingelheim. It acts as an angiokinase inhibitor.

Reference

1. Belani, C. P. (2010). The role of irreversible EGFR inhibitors in the treatment of non-small cell lung cancer: Overcoming resistance to reversible EGFR inhibitors. Cancer Investigation, 28(4), 413-423. https://pubmed.ncbi.nlm.nih.gov/20307200
2. Tomillero, A., & Moral, M. A. (2009). Gateways to clinical trials. Methods Find Exp Clin Pharmacol, 31(10), 661-700. https://pubmed.ncbi.nlm.nih.gov/20140276
3. Gazdar, A. F. (2010). Epidermal growth factor receptor inhibition in lung cancer: The evolving role of individualized therapy. Cancer Metastasis Reviews, 29(1), 37-48. https://pubmed.ncbi.nlm.nih.gov/20127143
4. Sos, M. L., Rode, H. B., Heynck, S., Peifer, M., Fischer, F., Klüter, S., Pawar, V. G., Reuter, C., Heuckmann, J. M., Weiss, J., Ruddigkeit, L., Rabiller, M., Koker, M., Simard, J. R., Getlik, M., Yuza, Y., Chen, T. H., Greulich, H., Thomas, R. K., & Rauh, D. (2010). Chemogenomic profiling provides insights into the limited activity of irreversible EGFR inhibitors in tumor cells expressing the T790M EGFR resistance mutation. Cancer Research, 70(3), 868-874. https://doi.org/10.1158/0008-5472.CAN-09-2747
5. Doebele, R. C., Oton, A. B., Peled, N., Camidge, D. R., & Bunn, P. A. Jr. (2010). New strategies to overcome limitations of reversible EGFR tyrosine kinase inhibitor therapy in non-small cell lung cancer. Lung Cancer. https://pubmed.ncbi.nlm.nih.gov/20092908
6. Regales, L., Gong, Y., Shen, R., de Stanchina, E., Vivanco, I., Goel, A., Koutcher, J. A., Spassova, M., Ouerfelli, O., Mellinghoff, I. K., Zakowski, M. F., Politi, K. A., & Pao, W. (2009). Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. Journal of Clinical Investigation, 119(10), 3000-3010. https://doi.org/10.1172/JCI38746
7. Ocaña, A., & Amir, E. (2009). Irreversible pan-ErbB tyrosine kinase inhibitors and breast cancer: Current status and future directions. Cancer Treatment Reviews, 35(8), 685-691. https://pubmed.ncbi.nlm.nih.gov/19733440
8. Nguyen, K. S., Kobayashi, S., & Costa, D. B. (2009). Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clinical Lung Cancer, 10(4), 281-289. https://pubmed.ncbi.nlm.nih.gov/19632948
9. Perera, S. A. et al. (2009). HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy. Proceedings of the National Academy of Sciences of the United States of America, 106(2), 474-479. https://doi.org/10.1073/pnas.0811326106
10. Minkovsky, N., & Berezov, A. (2008). BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Current Opinion in Investigational Drugs, 9(12), 1336-1346. https://pubmed.ncbi.nlm.nih.gov/19037840